796 related articles for article (PubMed ID: 23633119)
21. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
Rahsaz M; Azarpira N; Nikeghbalian S; Aghdaie MH; Geramizadeh B; Moini M; Banihashemi M; Darai M; Malekpour Z; Malekhosseini SA
Exp Clin Transplant; 2012 Feb; 10(1):24-9. PubMed ID: 22309416
[TBL] [Abstract][Full Text] [Related]
22. The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.
Furuse M; Hosomi S; Nishida Y; Itani S; Nadatani Y; Fukunaga S; Otani K; Tanaka F; Nagami Y; Taira K; Kamata N; Watanabe T; Watanabe K; Fujiwara Y
PLoS One; 2021; 16(4):e0250597. PubMed ID: 33886687
[TBL] [Abstract][Full Text] [Related]
23. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
24. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
[TBL] [Abstract][Full Text] [Related]
26. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
27. Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
Vanhove T; Bouillon T; de Loor H; Annaert P; Kuypers D
Clin Pharmacol Ther; 2017 Dec; 102(6):989-996. PubMed ID: 28437851
[TBL] [Abstract][Full Text] [Related]
28. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
[TBL] [Abstract][Full Text] [Related]
29. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
30. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients.
Qu J; Zhou BT; Yin JY; Xu XJ; Zhao YC; Lei GH; Tang Q; Zhou HH; Liu ZQ
CNS Neurosci Ther; 2012 Aug; 18(8):647-51. PubMed ID: 22630058
[TBL] [Abstract][Full Text] [Related]
31. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.
Wu P; Ni X; Wang M; Xu X; Luo G; Jiang Y
Ann Transplant; 2011; 16(1):54-60. PubMed ID: 21436775
[TBL] [Abstract][Full Text] [Related]
33. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
Kim IW; Moon YJ; Ji E; Kim KI; Han N; Kim SJ; Shin WG; Ha J; Yoon JH; Lee HS; Oh JM
Eur J Clin Pharmacol; 2012 May; 68(5):657-69. PubMed ID: 22183771
[TBL] [Abstract][Full Text] [Related]
34. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK
Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
[TBL] [Abstract][Full Text] [Related]
35. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
[TBL] [Abstract][Full Text] [Related]
36. Multigene predictors of tacrolimus exposure in kidney transplant recipients.
Pulk RA; Schladt DS; Oetting WS; Guan W; Israni AK; Matas AJ; Remmel RP; Jacobson PA;
Pharmacogenomics; 2015 Jul; 16(8):841-54. PubMed ID: 26067485
[TBL] [Abstract][Full Text] [Related]
37. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.
Birdwell KA; Grady B; Choi L; Xu H; Bian A; Denny JC; Jiang M; Vranic G; Basford M; Cowan JD; Richardson DM; Robinson MP; Ikizler TA; Ritchie MD; Stein CM; Haas DW
Pharmacogenet Genomics; 2012 Jan; 22(1):32-42. PubMed ID: 22108237
[TBL] [Abstract][Full Text] [Related]
38. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
39. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
40. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.
de Wildt SN; van Schaik RH; Soldin OP; Soldin SJ; Brojeni PY; van der Heiden IP; Parshuram C; Nulman I; Koren G
Eur J Clin Pharmacol; 2011 Dec; 67(12):1231-41. PubMed ID: 21698374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
